Gilead Sciences is strengthening its ties with Abu Dhabi's healthcare sector by expanding its collaboration with the World Health Organization (WHO).
What the collaboration means for Abu Dhabi
The US pharma giant's partnership with the WHO will focus on improving access to healthcare in the UAE capital, particularly in underserved communities. According to a spokesperson for Gilead Sciences, the collaboration will see the two parties work together on initiatives aimed at reducing healthcare disparities in Abu Dhabi. The partnership is expected to benefit over 100,000 people in the emirate, with a focus on improving maternal and child health. Gilead Sciences has committed to investing Dh10 million in the partnership, which will be used to support community-based health programs and research initiatives.
The collaboration comes as Abu Dhabi continues to invest heavily in its healthcare infrastructure, with a focus on cutting-edge medical research and treatment. The emirate has already made significant strides in this area, with the launch of the Abu Dhabi Health Authority's (ADHA) new healthcare strategy earlier this year. The strategy aims to improve healthcare outcomes and reduce healthcare costs in the emirate, with a focus on preventive care and early intervention.
A spokesperson for Gilead Sciences confirmed the move, saying: ''We are committed to working with the WHO to address healthcare challenges in Abu Dhabi and the wider region.'
Johnson & Johnson enters Department of Health collaboration
Meanwhile, Johnson & Johnson has entered a collaboration with the Abu Dhabi Department of Health to improve healthcare outcomes in the emirate. The partnership will see the two parties work together on a range of initiatives, including training programs for healthcare professionals and public health campaigns. Johnson & Johnson has committed to investing Dh5 million in the partnership, which will be used to support the development of new healthcare technologies and programs. The collaboration is expected to benefit over 50,000 people in the emirate, with a focus on improving healthcare outcomes for patients with chronic diseases.
A spokesperson for Johnson & Johnson said: ''We are excited to be working with the Department of Health to improve healthcare outcomes in Abu Dhabi.'
The partnership is part of Johnson & Johnson's wider commitment to improving healthcare outcomes in the Middle East and North Africa (MENA) region. The company has already made significant investments in the region, with a focus on developing new healthcare technologies and programs. Johnson & Johnson's collaboration with the Department of Health is expected to be a key part of its strategy in the region, with a focus on improving healthcare outcomes and reducing healthcare costs.
What this means for Abu Dhabi's healthcare sector
The collaborations mark a significant boost to Abu Dhabi's healthcare sector, which is already one of the most advanced in the region. The partnerships will see Gilead Sciences and Johnson & Johnson work together with the WHO and Department of Health to improve access to healthcare and drive innovation in the sector. The collaborations are expected to benefit over 150,000 people in the emirate, with a focus on improving healthcare outcomes and reducing healthcare costs. The partnerships are also expected to support the development of new healthcare technologies and programs, with a focus on improving healthcare outcomes for patients with chronic diseases.
The collaborations are part of Abu Dhabi's wider commitment to improving healthcare outcomes and reducing healthcare costs in the emirate. The emirate has already made significant strides in this area, with the launch of the Abu Dhabi Health Authority's (ADHA) new healthcare strategy earlier this year. The strategy aims to improve healthcare outcomes and reduce healthcare costs in the emirate, with a focus on preventive care and early intervention.
What's next for Gilead Sciences and Johnson & Johnson in Abu Dhabi
Gilead Sciences and Johnson & Johnson are expected to continue their collaborations with the WHO and Department of Health in the coming months. The partnerships are expected to be a key part of the companies' strategies in the MENA region, with a focus on improving healthcare outcomes and reducing healthcare costs. The collaborations are also expected to support the development of new healthcare technologies and programs, with a focus on improving healthcare outcomes for patients with chronic diseases. Gilead Sciences and Johnson & Johnson are expected to announce further details on their collaborations in the coming weeks and months.
